CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.

Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...

The World Health Organization (WHO) has reached a pivotal moment in the fight against COVID-19 by prequalifying the first two rapid antigen diagnostic tests for SARS-CoV-2. This groundbreaking ...

The Australian patent represents the first patent granted for the Company's new point-of-care testing platform ...

In a significant development in the fight against COVID-19, the World Health Organization (WHO) has prequalified two rapid antigen tests for detecting the virus. This landmark decision, announced last ...

In this interview, Dr. Denise Heaney discusses how molecular diagnostics are reshaping antimicrobial stewardship and ...

A further easing of animal movement restrictions has been announced for farms within the Bluetongue Virus (BTV) Temporary ...

WHO noted that prequalified tests can now be prioritized in pooled procurement mechanisms, which help lower prices, stabilize ...

IOC President Kirsty Coventry is ready to bring back the genetic tests that had been abandoned for over 30 years, and also ...

In winter, various respiratory infectious diseases such as influenza (flu), pneumonia, and COVID-19 are prevalent at the same ...

*The Co-Dx PCR platform (including the Co-Dx PCR Home (TM), Co-Dx PCR Pro (TM), mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is ...

Roche’s cobas BV/CV assay gains CE Mark, enabling accurate, rapid diagnosis of bacterial vaginosis and candida vaginitis.